T Cell Epitope Peptide Therapy for Allergic Diseases

Current Allergy and Asthma Reports

Volumn 16, Issue 2, 2016, Pages 1-9

  O’Hehir, Robyn E ^a   Prickett, Sara R ^a   Rolland, Jennifer M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Allergy; Immunotherapy; Peptide; SPIRE; Synthetic peptide immuno regulatory epitopes; T cell epitope

Indexed keywords

ANTIALLERGIC AGENT; CONTIGUOUS OVERLAPPING PEPTIDE; EPITOPE; FEL D 1 PEPTIDE; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLACEBO; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ALLERGEN; HLA ANTIGEN CLASS 2; PEPTIDE;

ALLERGIC DISEASE; ALLERGY; BRONCHOSPASM; CD4+ T LYMPHOCYTE; CHEST TIGHTNESS; CLONAL ANERGY; CYTOKINE RELEASE; CYTOKINE RESPONSE; EPITOPE MAPPING; FLUSHING; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INSECT ALLERGY; LYMPHOCYTE PROLIFERATION; NONHUMAN; NOSE OBSTRUCTION; POLLEN ALLERGY; PRURITUS; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TH2 CELL; ANIMAL; CLINICAL TRIAL (TOPIC); HYPERSENSITIVITY; IMMUNOLOGY;

ALLERGENS; ANIMALS; CLINICAL TRIALS AS TOPIC; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; HYPERSENSITIVITY; PEPTIDES;

EID: 84954309588     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-015-0587-0     Document Type: Review

References (93)

1. Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;177(4580):1555–626.
2. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–96 e3.
3. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009;64 Suppl 91:1–59.
4. Compalati E, Braido F, Canonica GW. An update on allergen immunotherapy and asthma. Curr Opin Pulm Med. 2014;20(1):109–17.
5. Kiel MA, Roder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Molken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013;132(2):353–60 e2.
6. Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol. 2009;103(6):451–9. quiz 9-61, 95.
7. Sandrini A, Rolland JM, O’Hehir RE. Current developments for improving efficacy of allergy vaccines. Expert Rev Vaccines. 2015;14:1073–87.
8. Prickett SR, Rolland JM, O'Hehir RE. Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy. Clin Exp Allergy. 2015;45(6):1015–26. Comprehensive review of strategies for designing T cell epitope-based peptide therapy for allergy.
9. Worm M. SPIREs: a new horizon for allergic disease treatment? Expert Rev Clin Immunol. 2015;11(11):1173–5.
10. O'Hehir RE, Hoyne GF, Thomas WR, Lamb JR. House dust mite allergy: from T-cell epitopes to immunotherapy. Eur J Clin Invest. 1993;23(12):763–72.
11. Hoyne GF, O'Hehir RE, Wraith DC, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med. 1993;178(5):1783–8.
12. Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci U S A. 1993;90(16):7608–12.
13. Bauer L, Bohle B, Jahn-Schmid B, Wiedermann U, Daser A, Renz H, et al. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clin Exp Immunol. 1997;107(3):536–41.
14. Norman PS, Ohman Jr JL, Long AA, Creticos PS, Gefter MA, Shaked Z, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1623–8.
15. Muller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998;101(6 Pt 1):747–54.
16. 4levels increased without evidence for adverse IgE mediated reactions.
17. Hafner RP, Couroux P, Armstrong K, Salapatek AM, Patel D, Larche M. Four doses of Der p derived synthetic peptide immuno-regulatory epitopes over 3 months results in a persistent treatment effect at 1 year on symptoms of House Dust Mite allergy. Allergy. 2014;69:31–2.
18. Worm M, Patel D, Creticos PS. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Expert Opin Investig Drugs. 2013;22(10):1347–57. Excellent review of development and clinical trial of T cell epitope peptide-based treatment for cat allergy, with evidence for a well-tolerated and promising new therapeutic approach.
19. Ellis AK, Frankish CW, Armstrong K, Larche M, O'Hehir RE, Steacey LM, et al. A short course of synthetic peptide immuno-regulatory epitopes derived from grass allergens leads to a reduction in grass allergy symptoms. Allergy. 2014;69:32.
20. Larche M. Mechanisms of peptide immunotherapy in allergic airways disease. Ann Am Thorac Soc. 2014;11 Suppl 5:S292–6. Critical appraisal of experimental evidence for mechanisms of peptide immunotherapy for allergy.
21. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med. 1983;157(5):1434–47.
22. Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol. 2010;11(8):674–80.
23. Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res. 2010;20(1):4–12.
24. Verhoef A, Higgins JA, Thorpe CJ, Marsh SG, Hayball JD, Lamb JR, et al. Clonal analysis of the atopic immune response to the group 2 allergen of Dermatophagoides spp.: identification of HLA-DR and -DQ restricted T cell epitopes. Int Immunol. 1993;5(12):1589–97.
25. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 1992;358(6382):155–7.
26. Wedderburn LR, O'Hehir RE, Hewitt CR, Lamb JR, Owen MJ. In vivo clonal dominance and limited T-cell receptor usage in human CD4+ T-cell recognition of house dust mite allergens. Proc Natl Acad Sci U S A. 1993;90(17):8214–8.
27. Aslam A, Chan H, Warrell DA, Misbah S, Ogg GS. Tracking antigen-specific T-cells during clinical tolerance induction in humans. PLoS One. 2010;5(6):e11028.
28. O'Hehir RE, Lake RA, Schall TJ, Yssel H, Panagiotopoulou E, Lamb JR. Regulation of cytokine and chemokine transcription in a human TH2 type T-cell clone during the induction phase of anergy. Clin Exp Allergy. 1996;26(1):20–7.
29. Hoyne GF, Askonas BA, Hetzel C, Thomas WR, Lamb JR. Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance in vivo. Int Immunol. 1996;8(3):335–42.
30. Wambre E, DeLong JH, James EA, Torres-Chinn N, Pfutzner W, Mobs C, et al. Specific immunotherapy modifies allergen-specific CD4(+) T-cell responses in an epitope-dependent manner. J Allergy Clin Immunol. 2014;133(3):872–9 e7. An elegant study in timothy grass pollen allergen immunotherapy utilizing an ex vivo peptide-MHC class II tetramer approach to demonstrate preferential deletion of allergen-specific Th2 cells.
31. Mannering SI, Dromey JA, Morris JS, Thearle DJ, Jensen KP, Harrison LC. An efficient method for cloning human autoantigen-specific T cells. J Immunol Methods. 2005;298(1-2):83–92.
32. Prickett SR, Voskamp AL, Dacumos-Hill A, Symons K, Rolland JM, O’Hehir RE. Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol. 2011;127(3):608–15 e1-5.
33. Oseroff C, Sidney J, Kotturi MF, Kolla R, Alam R, Broide DH, et al. Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J Immunol. 2010;185(2):943–55.
34. Kwok WW, Roti M, Delong JH, Tan V, Wambre E, James EA, et al. Direct ex vivo analysis of allergen-specific CD4+ T cells. J Allergy Clin Immunol. 2010;125(6):1407–9 e1.
35. Van Hemelen D, Mahler V, Fischer G, Fae I, Reichl-Leb V, Pickl W, et al. HLA class II peptide tetramers vs allergen-induced proliferation for identification of allergen-specific CD4 T cells. Allergy. 2015;70(1):49–58. Comprehensive comparison of two pivotal experimental approaches for identification and analysis of allergen-specific T cells.
36. Tye-Din JA, Stewart JA, Dromey JA, Beissbarth T, van Heel DA, Tatham A, et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med. 2010;2(41):41ra51.
37. Bateman EA, Ardern-Jones MR, Ogg GS. Identification of an immunodominant region of Fel d 1 and characterization of constituent epitopes.[see comment]. Clin Exp Allergy. 2008;38(11):1760–8.
38. Schulten V, Oseroff C, Alam R, Broide D, Vijayanand P, Peters B, et al. The identification of potentially pathogenic and therapeutic epitopes from common human allergens. Ann Allergy Asthma Immunol. 2013;110(1):7–10.
39. Lundegaard C, Lund O, Nielsen M. Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy? Expert Rev Vaccines. 2012;11(1):43–54.
40. Knapp B, Fischer G, Van Hemelen D, Fae I, Maillere B, Ebner C, et al. Association of HLA-DR1 with the allergic response to the major mugwort pollen allergen: molecular background. BMC Immunol. 2012;13:43.
41. Knapp B, Omasits U, Bohle B, Maillere B, Ebner C, Schreiner W, et al. 3-Layer-based analysis of peptide-MHC interaction: in silico prediction, peptide binding affinity and T cell activation in a relevant allergen-specific model. Mol Immunol. 2009;46(8-9):1839–44.
42. Maillere B, Mourier G, Herve M, Menez A. Fine chemical modifications at N- and C-termini enhance peptide presentation to T cells by increasing the lifespan of both free and MHC-complexed peptides. Mol Immunol. 1995;32(17-18):1377–85.
43. Mutschlechner S, Egger M, Briza P, Wallner M, Lackner P, Karle A, et al. Naturally processed T cell-activating peptides of the major birch pollen allergen. J Allergy Clin Immunol. 2010;125(3):711–8 8 e1–8 e2.
44. Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway Jr CA. Sequence analysis of peptides bound to MHC class II molecules. Nature. 1991;353(6345):622–7.
45. Immune Epitope Database and Analysis Resource [Internet]. [cited November 2015]. Available from: http://www.immuneepitope.org.
46. Salimi N, Fleri W, Peters B, Sette A. The immune epitope database: a historical retrospective of the first decade. Immunology. 2012;137(2):117–23.
47. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, Salimi N, et al. The immune epitope database 2.0. Nucleic Acids Res. 2010;38(Database issue):D854–62.
48. Vaughan K, Greenbaum J, Kim Y, Vita R, Chung J, Peters B, et al. Towards defining molecular determinants recognized by adaptive immunity in allergic disease: an inventory of the available data. J Allergy (Cairo). 2010;2010:628026.
49. Allergen Nomenclature, International Union of Immunological Societies [Internet]. [cited 2015]. Available from: http://www.allergen.org.
50. Gammon G, Sercarz E. How some T cells escape tolerance induction. Nature. 1989;342(6246):183–5.
51. Etto T, de Boer C, Prickett S, Gardner LM, Voskamp A, Davies JM, et al. Unique and cross-reactive T cell epitope peptides of the major Bahia grass pollen allergen, Pas n 1. Int Arch Allergy Immunol. 2012;159(4):355–66.
52. Jahn-Schmid B, Radakovics A, Luttkopf D, Scheurer S, Vieths S, Ebner C, et al. Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol. 2005;116(1):213–9.
53. Sone T, Dairiki K, Morikubo K, Shimizu K, Tsunoo H, Mori T, et al. Identification of human T cell epitopes in Japanese cypress pollen allergen, Cha o 1, elucidates the intrinsic mechanism of cross-allergenicity between Cha o 1 and Cry j 1, the major allergen of Japanese cedar pollen, at the T cell level. Clin Exp Allergy. 2005;35(5):664–71.
54. Drew AC, Eusebius NP, Kenins L, de Silva HD, Suphioglu C, Rolland JM, et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol. 2004;173(9):5872–9.
55. Prickett SR, Voskamp AL, Phan T, Dacumos-Hill A, Mannering SI, Rolland JM, et al. Ara h 1 CD4+ T-cell epitope-based peptides: candidates for a peanut allergy therapeutic. Clin Exp Allergy. 2013;43(6):684–97.
56. Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011;127(1):89–97 e1-14.
57. Santos AF, Douiri A, Becares N, Wu SY, Stephens A, Radulovic S, et al. Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children. J Allergy Clin Immunol. 2014;134(3):645–52.
58. McKinney DM, Southwood S, Hinz D, Oseroff C, Arlehamn CS, Schulten V, et al. A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. Immunogenetics. 2013;65(5):357–70.
59. ProImmune. ProImmune REVEAL® Class II Rapid Epitope Discovery System Accessed 2015. Available from: https://www.proimmune.com/ecommerce/page.php?page=reveal_class2.
60. Nepom GT. MHC class II tetramers. J Immunol. 2012;188(6):2477–82.
61. Crack LR, Chan HW, McPherson T, Ogg GS. Identification of an immunodominant region of the major house dust mite allergen Der p 2 presented by common human leucocyte antigen alleles. Clin Exp Dermatol. 2012;37(3):266–76.
62. Friedl-Hajek R, Spangfort MD, Schou C, Breiteneder H, Yssel H, Joost van Neerven RJ. Identification of a highly promiscuous and an HLA allele-specific T-cell epitope in the birch major allergen Bet v 1: HLA restriction, epitope mapping and TCR sequence comparisons. Clin Exp Allergy. 1999;29(4):478–87.
63. DeLong JH, Simpson KH, Wambre E, James EA, Robinson D, Kwok WW. Ara h 1-reactive T cells in individuals with peanut allergy. J Allergy Clin Immunol. 2011;127(5):1211–8 e3.
64. Castelli FA, Buhot C, Sanson A, Zarour H, Pouvelle-Moratille S, Nonn C, et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol. 2002;169(12):6928–34.
65. O'Hehir RE, Yssel H, Verma S, de Vries JE, Spits H, Lamb JR. Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int Immunol. 1991;3(8):819–26.
66. Faith A, Akdis CA, Akdis M, Simon HU, Blaser K. Defective TCR stimulation in anergized type 2 T helper cells correlates with abrogated p56(lck) and ZAP-70 tyrosine kinase activities. J Immunol. 1997;159(1):53–60.
67. Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield WL, Stern LJ, et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med. 2009;206(7):1535–47.
68. Mackenzie KJ, Fitch PM, Leech MD, Ilchmann A, Wilson C, McFarlane AJ, et al. Combination peptide immunotherapy based on T-cell epitope mapping reduces allergen-specific IgE and eosinophilia in allergic airway inflammation. Immunology. 2013;138(3):258–68.
69. Wallner BP, Gefter ML. Immunotherapy with T-cell-reactive peptides derived from allergens. Allergy. 1994;49(5):302–8.
70. Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med. 1999;189(12):1885–94.
71. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol. 1999;93(3):222–31.
72. Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol. 1996;8(12):1937–45.
73. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet. 2002;360(9326):47–53.
74. Larche M. Peptide immunotherapy for allergic diseases. Allergy. 2007;62(3):325–31.
75. Larche M. T cell epitope-based allergy vaccines. Curr Top Microbiol Immunol. 2011;352:107–19.
76. Smith TR, Alexander C, Kay AB, Larche M, Robinson DS. Cat allergen peptide immunotherapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study. Allergy. 2004;59(10):1097–101.
77. Creticos PS. Advances in synthetic peptide immuno-regulatory epitopes. World Allergy Organ J. 2014;7(1):30.
78. Couroux P, Patel D, Armstrong K, Larche M, Hafner RP. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy. 2015;45(5):974–81. Demonstration of sustained clinical efficacy (cat exposure chamber challenge) out to two years after course of 4 treatments with cat allergen peptides at 4-week intervals.
79. Narkus A, Lehnigk U, Haefner D, Klinger R, Pfaar O, Worm M. The placebo effect in allergen-specific immunotherapy trials. Clin Transl Allergy. 2013;3(1):42.
80. Durham SR. Sublingual immunotherapy: what have we learnt from the 'big trials'? Curr Opin Allergy Clin Immunol. 2008;8(6):577–84.
81. Larche M, Hickey P, Hebert J, Hafner R. Safety and tolerability of escalating doses of house dust mite- peptide antigen desensitization (HDM-PAD). J Allergy Clin Immunol. 2013;131(2):Ab37-Ab.
82. Ellis A, Frankish CW, Armstrong K, Larche M, Steacy L, Hafner R, et al. Persistent Treatment Effect with Grass Synthetic Peptide Immuno-Regulatory Epitopes in Grass Allergy Symptoms in an Environmental Exposure Unit Challenge after a Second Season of Natural Pollen Exposure. J Allergy Clin Immunol. 2015;135(2):Ab158-Ab.
83. Hafner R, Salapatek A, Patel D, Larche M, Laidler P. Validation of peptide immunotherapy as a new approach in the treatment of allergic rhinoconjunctivitis: The clinical benefits of treatment with Amb a 1-derived T cell epitopes. J Allergy Clin Immunol. 2012;129(2):AB368.
84. Pellaton C, Perrin Y, Boudousquie C, Barbier N, Wassenberg J, Corradin G, et al. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy. 2013;3(1):17.
85. Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol. 2003;111(4):854–61.
86. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med. 2005;11(4 Suppl):S69–76.
87. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133(3):621–31.
88. O'Hehir RE, Sandrini A, Anderson GP, Rolland JM. Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation. Curr Med Chem. 2007;14(21):2235–44.
89. Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy. 2006;36(4):465–74.
90. Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med. 2005;2(3):e78.
91. Alexander C, Ying S, Kay AB, Larche M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma + T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy. 2005;35(1):52–8.
92. Rolland JM, Gardner LM, O'Hehir RE. Functional regulatory T cells and allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2010;10(6):559–66.
93. Plaut M, Rotrosen D. Tolerance induced by allergen immunotherapy. Clin Allergy Immunol. 2004;18:681–702.